<DOC>
	<DOCNO>NCT00898846</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue laboratory patient cancer may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This laboratory study look prognostic factor patient receive tegafur-uracil stage II colon cancer completely remove surgery .</brief_summary>
	<brief_title>Identifying Prognostic Factors Patients Receiving Tegafur-Uracil Stage II Colon Cancer That Was Completely Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Identify prognostic factor patient curatively resect stage II colon cancer receive adjuvant chemotherapy tegafur-uracil . - Identify predictive factor chemosensitivity regimen patient . OUTLINE : Available tumor tissue sample analyze real-time reverse transcriptase-PCR TS , DPD , TP , OPRT , VEGF , cyclooxygenase-2 , FPGS ; PCR microsatellite instability genomic deletion chromosome arm 18q ; pathologically tumor bud , Crohn's-like lymphoid reaction , category extent poor differentiation , fibrotic cancer stroma . The candidate prognostic predictive marker analyze correlation disease-free survival , relapse-free survival , overall survival patient .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectosigmoid Stage II disease Must register clinical trial TMDUBRICC0501 Must resect tumor tissue available No hereditary colorectal cancer PATIENT CHARACTERISTICS : ECOG performance status 01 PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>